CG On­col­o­gy reels in $105M crossover for po­ten­tial late 2024 blad­der can­cer drug fil­ing

CG On­col­o­gy, out to treat blad­der can­cer pa­tients left be­hind by the short­age of Mer­ck’s stan­dard BCG ther­a­py or didn’t ben­e­fit from it in the first place, has reeled in a $105 mil­lion crossover fi­nanc­ing.

The Cal­i­for­nia biotech an­tic­i­pates a Phase III topline read­out for a monother­a­py ver­sion of its on­colyt­ic virus can­di­date by year’s end and then a reg­u­la­to­ry ap­proval fil­ing in late 2024 or ear­ly 2025, CEO Arthur Kuan told End­points News in a pre­view of the fund­ing round, which was dis­closed Wednes­day morn­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER